|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Shire was the seventh-largest holding in Cooperman's Omega Advisors’ portfolio in 2Q17, representing nearly 3.5% of total holdings.